Europe PMC
Cure8 research brief
The Oral–Gut Microbiome Axis in Gastrointestinal and Systemic Diseases
Research and clinical trials
Microbiome
Biomarkers
Biomarker
Basic Science
Researchers
Clinicians
Adult patients
Why This Matters
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors (oral health, antibiotics, acid suppression) that may affect the oral–gut axis.
Who Should Pay Attention
Researchers studying the microbiome or IBD mechanisms, clinicians interested in noninvasive biomarkers or prevention strategies, and patients curious about connections between oral health and gut disease.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper outlines mechanisms by which oral microbes can reach and affect the gut: migration in saliva, weakening of colonization resistance (for example after antibiotics or gastric-acid changes), immune signaling, metabolite exchange, and inflammation-driven feedback loops.
It highlights associations between periodontal disease/oral dysbiosis and gastrointestinal disorders, with IBD and colorectal cancer noted as having stronger mechanistic support so far. The authors emphasize that most human associations do not yet prove causality.
They call for longitudinal cohorts, standardized sampling, mechanistic studies, and integration of microbial, metabolic, immune, and clinical datasets before clinical applications (like saliva-based biomarkers or targeted oral interventions) can be widely adopted.
Keep In Mind
Preprint/abstract-level synthesis: useful for understanding current hypotheses and research needs but not a source of proven clinical interventions. Many associations remain correlative; longitudinal and mechanistic studies are needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEurope PMC
AuthorsYaqub MO, Arugonda R, Jain A +6 more
Study typePreprint
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
Inflammation-driven carcinogenesis in ulcerative colitis: Molecular and immunological pathways
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
Machine Learning Model Identifies Gut Biomarkers That May Help Diagnose IBD Patients
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.